Liraglutide in oral antidiabetic drug combination therapy.
Author(s): Garber AJ.
Affiliation(s): Division of Endocrinology, Diabetes and Metabolism, Baylor College of Medicine,
Houston, TX 77030, USA. agarber@bcm.tmc.edu
Publication date & source: 2012, Diabetes Obes Metab. , 14 Suppl 2:13-9
The glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide is indicated as
an add-on to oral antidiabetic drug regimens in subjects with type 2 diabetes.
Herein, the results of clinical trials assessing the efficacy, safety and
tolerability of liraglutide when used in combination with either one or two oral
antidiabetic therapies are summarised, then contrasted with the effects of
exenatide and dipeptidyl peptidase (DPP-4) inhibitors. GLP-1 receptor agonists
lead to effective glycaemic control when used as combination therapy with either
one or two oral antidiabetic agents, and may confer overall benefits in weight
loss and blood pressure in some subjects. These agents are well tolerated; the
most commonly reported adverse effect is mild-to-moderate gastrointestinal
symptoms, which are usually transient. Rates of hypoglycaemia in these trials
were low, although higher rates were noted when combined with a sulphonylurea.
While further study will be required, GLP-1 receptor agonists may offer important
advantages over other diabetic therapies, including DPP-4 inhibitors.
|